Tech Company Financing Transactions
Primmune Therapeutics Funding Round
Primmune Therapeutics, based in San Diego, secured investment capital from Bioqube Ventures, Oberland Capital and Samsara BioCapital.
Transaction Overview
Company Name
Announced On
1/26/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Proceeds Purpose
These funds will be used to support the further clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3210 Merryfield Row
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles McDermott
Vice President
Stephen Webber
VP - Bus. Development
Paulo Rangel
VP - R & D
James Appleman
Browse more venture capital transactions:
Prev: 1/26/2026: Mine venture capital transaction
Next: 1/26/2026: GlassPoint venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs